- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02490865
Systemic Bioactivity of Inhaled Nebulized RNS60
September 18, 2015 updated by: Revalesio Corporation
The study aims to determine the effects of nebulized RNS60 on selected biomarkers in the circulation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The study is a double-blind, placebo controlled, parallel design study.
Participants will be randomized to receive 2 daily doses of either nebulised RNS60 or placebo (n=28 per group) for 22 days.
On day 19 they will undergo an exercise protocol to induce muscle damage and blood samples will be taken on days 19, 20, 21 and 23 to determine the effects on CK and hsCRP.
ROM and pain VAS assessments will also be completed.
Study Type
Interventional
Enrollment (Actual)
56
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Surrey
-
Guildford, Surrey, United Kingdom, GU2 7XP
- Surrey Clinical Research Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The participant is able to read and understand the Informed Consent Form (ICF), and understand study procedures.
- The participant has signed the ICF.
- Healthy male or female participants aged 18-45 years inclusive. Attempts will be made to achieve an equal gender ratio through appropriate screening procedures, but a failure to do so will not preclude analysis of the final data set.
- BMI between 19 and 27 kg/m2.
- The participant is, in the opinion of the investigator, healthy on the basis of medical history and vital signs.
- Available for follow-up for the duration of the study.
- Non-smokers (no smoking or use of nicotine replacements (including e-cigarettes) in the previous month before screening or during the study)
- Agree to abstain from donating blood during the study.
- Men and women of reproductive potential who document use of adequate contraception during the study and for 1 month following the last day of treatment (Day 23)
- Willing to refrain from taking anti-inflammatory medications during the study (particularly ibuprofen).
Exclusion Criteria:
- Clinically significant psychiatric, cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological (particularly myasthenia gravis), immunological, or haematological disease or abnormality, as determined by the study physician.
- History of alcohol, narcotic, benzodiazepine, or other substance abuse or dependence within the 12 months preceding Visit 1.
- History of significant musculoskeletal upper limb injury.
- Participating in regular (≥ 2 times per week) upper body resistance exercise training within 6 weeks of Visit 1.
- FEV1 < 80% or FEV1/FEC of < 75%
- Use of steroids or immunosuppressive/immunomodulating drugs either orally or parenterally within 3 months of Visit 1.
- Use of NSAIDs and other OTC medications within 2 weeks of Visit 1.
- Use of any dietary/nutritional supplements, including vitamins and minerals, in the 2 weeks before Visit 1.
- Positive urinary pregnancy test.
- Pregnant or lactating at any point during the study from screening to final visit.
- Following a weight reducing diet.
- Currently participating in another clinical trial with an investigational or non-investigational drug or device, or has participated in another clinical trial within the 3 months preceding Visit 1.
- Any condition that, in the investigator's opinion, compromises the participant's ability to meet protocol requirements or to complete the study.
- Receipt of blood products or immunoglobin, within 3 months of visit 1.
- Unable to read and speak English to a fluency level adequate for the full comprehension of procedures required in participation and consent.
No waivers from the Protocol will be allowed.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RNS60
Administration of nebulized RNS60 to test for systemic bioactivity
|
RNS60, 4 ml dose nebulized twice daily
|
Placebo Comparator: Normal Saline
Administration of normal saline used as control
|
Normal Saline, 4 ml dose nebulized twice daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in serum concentration of creatine kinase (CK)
Time Frame: 4 days post exercise
|
4 days post exercise
|
Change in serum concentration of highly sensitive C-reactive protein (hsCRP)
Time Frame: 4 days post exercise
|
4 days post exercise
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2015
Primary Completion (Actual)
August 1, 2015
Study Completion (Actual)
August 1, 2015
Study Registration Dates
First Submitted
July 2, 2015
First Submitted That Met QC Criteria
July 2, 2015
First Posted (Estimate)
July 7, 2015
Study Record Updates
Last Update Posted (Estimate)
September 22, 2015
Last Update Submitted That Met QC Criteria
September 18, 2015
Last Verified
September 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 08.1.2.H8
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Bioactivity of Nebulized RNS60
-
Medical University of GdanskCompletedInfluence of Nebulized Bronchodilatators on Selected | Electrophysiological ParametersPoland
-
Chiesi Farmaceutici S.p.A.CompletedPartial Obstruction of Systemic to Pulmonary Artery Shunt | Complete Obstruction of Systemic to Pulmonary Artery ShuntUnited States
-
University of CologneCompletedControl of Elevated Eye Pressure by Local and Systemic TherapyGermany
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...Aristopharma LtdRecruitingEfficacy of Tofacitinib in the Systemic SclerosisBangladesh
-
University of AberdeenKellogg CompanyCompletedBio-availability of Wheat Bran Phytochemicals in the Human Gut | Bio-availability of Wheat Bran Phytochemicals for the Systemic CirculationUnited Kingdom
-
CHU de ReimsNot yet recruitingValidation of Raman Spectroscopy Usefulness in Systemic SclerosisFrance
-
IRCCS Azienda Ospedaliera Universitaria San Martino...CompletedDiffusion Limitation of Pulmonary Gas Exchange in Systemic Sclerosis
-
Thomas Jefferson UniversityActive, not recruitingPain | Quality of Recovery | Local Anesthetic Systemic ToxicityUnited States
-
Michigan State UniversityThe Hospital for Sick Children; University of Alabama at Birmingham; United States... and other collaboratorsNot yet recruitingSystemic Lupus Erythematosus of Childhood (Disorder)
-
Hadassah Medical OrganizationUnknownFemale Patients Aged 5-35 Prior to Systemic Chemotherapy | With Significant Risk of Ovarian ToxicityIsrael
Clinical Trials on RNS60
-
Revalesio CorporationCompleted
-
Revalesio CorporationWithdrawnRelapsing Remitting Multiple SclerosisUnited States
-
Craig L Slingluff, JrUniversity of VirginiaCompletedMelanoma | Metastatic Melanoma | Mucosal MelanomaUnited States
-
Mario Negri Institute for Pharmacological ResearchALS Association; Get out ONLUSCompleted
-
Revalesio CorporationWithdrawnAnterior Cruciate Ligament Reconstruction
-
Revalesio CorporationCompletedStroke, IschemicUnited States
-
Revalesio CorporationNot yet recruitingAmyotrophic Lateral Sclerosis
-
Revalesio CorporationWithdrawn
-
Revalesio CorporationCompleted
-
Revalesio CorporationWithdrawn